L. Lallos

发表

In vitro Activity and Resistance Profile of Samatasvir , a Novel NS 5 A Replication Inhibitor 1 of Hepatitis C Virus 2

J. Bilello, J. McCarville, L. Lallos, 2014 .

In Vitro Activity and Resistance Profile of Samatasvir, a Novel NS5A Replication Inhibitor of Hepatitis C Virus

J. Bilello, J. McCarville, L. Lallos, 2014, Antimicrobial Agents and Chemotherapy.

Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.

Catherine Caillet, S. Cappelle, M. Liuzzi, 2014, Bioorganic & medicinal chemistry letters.

Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection

Tara L. Kieffer, A. Kwong, M. Tausek, 2008 .

HIV phenotype correlates with the relative amounts of lymphocyte function-related molecule 1 (LFA-1) and major histocompatibility complex (MHC) class II in the virion envelope

S. Zolla-Pazner, E. Fenyö, S. Laal, 2000, AIDS (London).

Exclusion of HIV coreceptors CXCR4, CCR5, and CCR3 from the HIV envelope.

J. Hoxie, S. Zolla-Pazner, S. Laal, 1999, AIDS research and human retroviruses.

In Vitro Activity and Resistance Proﬁle of Samatasvir, a Novel NS5A Replication Inhibitor of Hepatitis C Virus

J. Bilello, J. McCarville, L. Lallos, 2014 .

Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.

Catherine Caillet, S. Cappelle, M. Liuzzi, 2015, Bioorganic & medicinal chemistry letters.

Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.

Catherine Caillet, M. Liuzzi, C. Musiu, 2015, Bioorganic & medicinal chemistry letters.

588 IN VITRO ANTIVIRAL ACTIVITY AND PHARMACOLOGY OF IDX184, A NOVEL AND POTENT INHIBITOR OF HCV REPLICATION

L. Licklider, J. Bilello, J. McCarville, 2008 .